Companies · Other Health Care

General Prognostics, Inc.

Boston · Other Health Care

Diligence memoA one-page analyst read on General Prognostics, Inc. — recommendation, valuation, rhythm, risks.
$810K
Total raised · real
2
Rounds
0.3×
Latest step-up
Top 72%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Fri Jun 28 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

General Prognostics, Inc. looks under-valued against its niche peers and is quiet on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.33× the median modeled value of Pre-Seed Other Health Care companies in 2022–2024 (288 peers) — value vs value, same stage and era.
Quiet
  • Last raise 2.0 yr ago; this sector typically re-raises about every 14 months.
  • Slightly overdue versus sector cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

General Prognostics, Inc. is one of 5376 Other Health Care companies tracked from Boston. By capital raised it ranks in the long tail (ahead of 29% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
2
Investors (latest)
2020
Year incorporated
2024-06-28
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$5.0M$10M$15M$20MPre-Seed · 2020-10-29 Raised $610K (real) Modeled valuation $16M (est)$610K$16MPre-Seed2020Pre-Seed · 2024-06-28 Raised $200K (real) Modeled valuation $849K (est)$200K$849KPre-Seed2024+$200KCumulative $810K

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$610K · 2020
Pre-Seed extension$200K · 2024

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$849K
Base estimate est.
$125K
Conservative case
$2.9M
Upside case
$1.1M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $16.0M · 2020-10-292020Pre-Seed · modeled $849K · 2024-06-282024
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
28%
Survival probability
11% low · 52% high
1.64×/yr
Annual markup
2.23×/yr upside case
2.0 yr
Elapsed time used
2.0 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
44 mo
Avg between rounds
$221K/yr
Capital velocity
5.7 yr
On record since
2020
First round
2
Rounds on file
How it compares to the market

Benchmarked against 5376 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.3× of median
This company$810K
Sector median$2.4M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 0.6× of median
This company$200K
Sector median$350K
Modeled value — vs sector median (estimate, all stages) 0.0× of median
This company$849K
Sector median$22.1M

Raised more than 29% of sector peers (real $). Modeled value above 5% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #230 of 288.

This companyCohort peer
$100K$1.0M$10.0M$100.0M$100K$1.0M$10.0MCapital raised (log)Active Recovery TMS, LLC · Pre-Seed Raised $1.0M · modeled $14.1M (est)Imagen Walled Lake Support Services, LLC · Pre-Seed Raised $977K · modeled $12.9M (est)Pinnacle Integrated Medicine, Inc. · Pre-Seed Raised $2.3M · modeled $12.3M (est)Choix, Inc. · Pre-Seed Raised $1000K · modeled $12.2M (est)DataBiologics, Inc. · Pre-Seed Raised $815K · modeled $11.2M (est)DIAGGO, Inc. · Pre-Seed Raised $1.0M · modeled $11.1M (est)American Nitrile Intermediate Holdings, LLC · Pre-Seed Raised $1.8M · modeled $10.4M (est)2636696 Ontario Inc. · Pre-Seed Raised $1.3M · modeled $9.9M (est)Exo-Toe, Llc · Pre-Seed Raised $1.2M · modeled $9.6M (est)RoddyMedical Holdings, Inc. · Pre-Seed Raised $915K · modeled $9.6M (est)Phoeb-X, Inc. · Pre-Seed Raised $912K · modeled $9.5M (est)NeuroGlove, LLC · Pre-Seed Raised $1.0M · modeled $9.1M (est)General Prognostics, Inc. (this company) Raised $810K · modeled $849K (est)General Prognostics, Inc.
CompanyStageRaised · realValue · estvs peer med.
Active Recovery TMS, LLCPre-Seed$1.0M$14.1M5.51×
Imagen Walled Lake Support Services, LLCPre-Seed$977K$12.9M5.05×
Pinnacle Integrated Medicine, Inc.Pre-Seed$2.3M$12.3M4.81×
Choix, Inc.Pre-Seed$1000K$12.2M4.78×
DataBiologics, Inc.Pre-Seed$815K$11.2M4.37×
DIAGGO, Inc.Pre-Seed$1.0M$11.1M4.35×
American Nitrile Intermediate Holdings, LLCPre-Seed$1.8M$10.4M4.07×
2636696 Ontario Inc.Pre-Seed$1.3M$9.9M3.87×
Exo-Toe, LlcPre-Seed$1.2M$9.6M3.77×
RoddyMedical Holdings, Inc.Pre-Seed$915K$9.6M3.76×
Phoeb-X, Inc.Pre-Seed$912K$9.5M3.71×
NeuroGlove, LLCPre-Seed$1.0M$9.1M3.56×
General Prognostics, Inc. this companyPre-Seed$810K$849K0.33×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$610K2020-10-29$3.4M$16.0M90%
Pre-Seed$200K2024-06-28$1.1M$849K90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$610K2020-10-29
    • First recorded raise — entered as Pre-Seed.
    • 8 investors on this round.
  2. Pre-Seed$200K2024-06-28
    • Raised again after 44 mo — slower than the ~14 mo sector norm.
    • Round 3.1× smaller than the prior — bridge or down round.
    • 2 investors on this round.
Intelligence
2028 ~Q1
Modeled next raise · ~44mo cadence
$200K
Modeled next size est.range $200K$320K
0.3×
Last step-up
$221K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Javier Echenique2020-10
Sean Matsuoka2020-10
Registry & provenance

General Prognostics, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1940780
SEC CIK
2020
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Pollie, Inc.Other Health CarePre-Seed$815K$906Ksame sector · same stage
Massachusetts Avenue Surgery Center, LLCOther Health CarePre-Seed$805K$570Ksame sector · same stage
OneCare, LLCOther Health CarePre-Seed$850K$1.3Msame sector · same stage
North Texas Renal Management XI, LLCOther Health CarePre-Seed$771K$1.2Msame sector · same stage
River Valley ASC, LLCOther Health CarePre-Seed$750K$489Ksame sector · same stage
Assist Enterprises LlcOther Health CarePre-Seed$750K$1.2Msame sector · same stage
Five To Thrive, LLCOther Health CarePre-Seed$750K$1.2Msame sector · same stage
Freedom Health Group CorpOther Health CarePre-Seed$750K$1.2Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
PrognomIQ, Inc.Other Health CareSeries B$49.0M92%
Sera Prognostics, Inc.Other Health CareSeries D+$2.0B89%
Prognos Health Inc.HealthtechSeries B$235.0M87%
NOWDiagnostics, Inc.Other Health CareSeries B$420.4M85%
Protean Biodiagnostics Inc.Other Health CareSeries A$35.4M84%
OutcomeMD, Inc.Other Health CareSeries B$74.6M83%
Glyscend, Inc.Other Health CareSeries A$96.9M83%
GLW, Inc.Other Health CareSeries A$48.5M82%
Frequently asked
How much funding has General Prognostics, Inc. raised?
General Prognostics, Inc. has raised approximately $810K in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is General Prognostics, Inc.'s estimated valuation?
Provath's modeled valuation for General Prognostics, Inc. is approximately $849K (modeled range $125K–$2.9M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is General Prognostics, Inc. at?
General Prognostics, Inc.'s latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Fri Jun 28.
What does General Prognostics, Inc. do and where is it based?
General Prognostics, Inc. operates in the Other Health Care sector, based in Boston.
Explore related

See where General Prognostics, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at General Prognostics, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.